We have developed a differentiated pipeline of clinical-stage and preclinical drug candidates by leveraging our proprietary antibody discovery and development platforms. MIL62 is a novel 3rd-generation anti-CD20 antibody and has been granted BTD by NMPA in China for the treatment of primary membranous nephropathy (PMN). It is expected to become the first approved targeted therapy for PMN. MBS303/MSC303 is an innovative CD20/CD3 T-cell engager (TCE) with the potential to benefit?B-NHL and immune-mediated glomerulonephritis patients. MBS314 is an innovative GPRC5D/BCMA/CD3 TCE providing a potential optimal solution for multiple myeloma patients.
| Category | Candidate | Target | Indication | Preclinical | IND | Phase I | Phase II | Registration Trial | Application | Progress* and Upcoming Milestone | Partner |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Pipeline | MIL62 | Third-generation CD20 (ADCC-enhanced) | Primary membranous nephropathy (PMN) | Phase III trial (recruitment completed) | |||||||
| Follicular lymphoma(FL) | Phase III trial (recruiting) |
||||||||||
| Systemic Lupus Erythematosus（SLE） | Phase II/III trial (recruiting) | ||||||||||
| Neuromyelitis optical spectrum disorder (NMOSD) | Phase Ib/III trial (recruiting) | ||||||||||
| Primary Pipeline | MBS303/MSC303 | CD20/CD3 | B cell non-Hodgkin Lymphoma (B-NHL) | Phase I/II trial (recruiting) | |||||||
| Immune-mediated Glomerulonephritis | IND approved | ||||||||||
 MBS314 |
GPRC5D/BCMA/CD3 | Multiple Myeloma（MM） | Phase I/II trial (recruiting) | ||||||||
| Other Pipeline | MIL86 | PCSK9 | Hyperlipidemia | Phase II trial (completed) | |||||||
| MIL93 | Claudin 18.2 (ADCC-enhanced) | Claudin 18.2-positive gastric cancer, gastroesophageal junction cancer and pancreatic cancer | Phase I/II trial (recruiting) | ||||||||
| MIL98 | LAG3 | Melanoma, late-stage lymphoma and other late-stage malignant solid tumors | Phase I trial (completed) | ||||||||
| MIL97 | CD40 | Metastatic pancreatic cancer and other solid tumors | Phase I trial (completed) | ||||||||
Core Pipeline
Primary Pipeline
Other Pipeline
Planned trial to be initiated
Collaborative pipeline
